<DOC>
	<DOCNO>NCT01844648</DOCNO>
	<brief_summary>To study safety efficacy tropicamide 1 mg intra-oral slow dissolve muco-adhesive thin film compare placebo reduce hypersalivation PD patient manifest sialorrhea complaint .</brief_summary>
	<brief_title>Study Safety Efficacy Tropicamide Thin Films Reduce Hypersalivation Parkinson 's Patients</brief_title>
	<detailed_description>This double-blind , placebo-controlled , randomize , crossover , multicentre study compare intra-oral slow dissolve muco-adhesive thin film contain tropicamide 1 mg Placebo . Patients receive treatment twice daily ( 1 h breakfast 1 h lunch ) 1-week . Patients evaluated eligibility 14-day screening period . Those patient meet entry criterion baseline randomize ( 1:1 ) receive first tropicamide follow placebo film vice versa . Patients return regularly schedule visit Weeks 1 3 early discontinuation .</detailed_description>
	<mesh_term>Sialorrhea</mesh_term>
	<mesh_term>Tropicamide</mesh_term>
	<criteria>Inclusion criterion : Patients idiopathic Parkinson 's disease , accord UK Brain Bank criterion . Patients complain drooling , score least 6 point SCSPD scale . Patients 30 year old . Patients Hoehn &amp; Yahr score IIV . Male nonpregnant female . Females childbearing potential require undergone pregnancy test negative result prior entry study agree use contraceptive measure duration study . Patients must use antiparkinsonian medication dose last month . No change medication PD expect study . Exclusion criterion : Pregnant woman . Patients secondary parkinsonian syndrome , parkinsonismplus syndrome , heredodegenerative disorder benign parkinsonism . Patients diagnosis major depression psychosis accord DSMIV . Patients MMSE score equal low 24 . Patients current diagnosis substance abuse ( DSMIV ) history alcohol drug abuse past 3 month . Patients hallucination . Patients current clinically significant gastrointestinal , renal , hepatic , endocrine , pulmonary cardiovascular disease , include hypertension wellcontrolled , asthma , chronic obstructive pulmonary disease ( COPD ) Type I diabetes . Patients second thirddegree atrioventricular block sick sinus syndrome , uncontrolled atrial fibrillation , severe unstable angina , congestive heart failure , myocardial infarction within 3 month screen visit , significant ECG abnormality , include QTc ≥ 450 msec ( male ) ≥ 470 msec ( female ) , QTc base Bazett 's correction method . Patient neoplastic disorder , either currently active remission less one year . Patients history current diagnosis HIV , test positive Hepatitis B C antibody , Hepatitis B surface antigen Patients participate previous clinical trial within 30 day entry study ( screen visit ) receive treatment investigational compound within 30 day . Patients hypersensitivity atropine anticholinergic drug . Patients experienced adverse effect result take anticholinergic drug . Patients receive anticholinergic drug anticholinesterase agent . Patients start change dose follow medication previous week : tricyclic antidepressant , monoamine oxidaseA inhibitor , antipsychotic , benzodiazepine , opioids , antihistamine , carbamazepine , NSAIDs . Patients significant dental/oral pathology . Patient abnormality investigator deem clinically relevant , either medical history , physical examination , ECG diagnostic laboratory test . Patients closedangle Glaucoma high risk suffer treatment anticholinergic agent . Patients Prostatic Adenoma . In judgment Clinical Investigator , patient likely noncompliant uncooperative study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Sialorrhea</keyword>
	<keyword>Tropicamide</keyword>
	<keyword>Non-motor symptom</keyword>
	<keyword>Thin strip delivery</keyword>
</DOC>